Patents by Inventor Gregory D. Cuny

Gregory D. Cuny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9682983
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 20, 2017
    Assignees: The Brigham and Women's Hospital, Inc., Dept. of Health and Human Services, National Institutes of Health
    Inventors: Asaf Alimardanov, Gregory D. Cuny, Gurmit Singh Grewal, Arthur Lee, John C. McKew, Agustin H. Mohedas, Min Shen, Xin Xu, Paul B. Yu
  • Publication number: 20170107228
    Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.
    Type: Application
    Filed: June 15, 2015
    Publication date: April 20, 2017
    Inventors: Gregory D. CUNY, Marcie A. GLICKSMAN, Kevin J. HODGETTS, Steven L. MATHIEU, Yukari Y. PERRELLA, Vincent DARMENCY, Hrvoje LUSIC
  • Publication number: 20170095481
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Application
    Filed: August 18, 2016
    Publication date: April 6, 2017
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Publication number: 20170088515
    Abstract: Herein, compounds and compositions for use in treating diseases relating to inclusion formation and stress granules are described. Methods for screening for modulation of TDP-43 aggregation are also described.
    Type: Application
    Filed: May 2, 2016
    Publication date: March 30, 2017
    Inventors: Benjamin Wolozin, Marcie Glicksman, Gregory D. Cuny, Justin Boyd
  • Patent number: 9556129
    Abstract: This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such disorders include obesity and disorders associated with obesity.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: January 31, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: David Cohen, Neil Wagle, Gregory D. Cuny, Jun Xian, Marcie Glicksman, Ross L. Stein, Ekaterina Y. Shishova
  • Patent number: 9518032
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: December 13, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Alan D. D'Andrea, Gregory D. Cuny, Ross L. Stein, Marcie Glicksman, April Case, Jun Xian, David Wilson, Min Huang
  • Patent number: 9447075
    Abstract: Pyridazine derivatives that activate the excitatory amino acid transporter 2 (EAAT2), and methods use thereof for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: September 20, 2016
    Assignees: The Brigham and Women's Hospital, Inc., The Ohio State University
    Inventors: Gregory D. Cuny, Marcie Glicksman, Xeuchao Xing, Chien-Liang Glenn Lin
  • Patent number: 9447134
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound selectively inhibits a parasitic IMPDH versus a host IMPDH. Also disclosed are pharmaceutical compositions comprising one or more compounds of the invention. Related methods of treating various parasitic and bacterial infections in mammals are disclosed. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: September 20, 2016
    Assignees: Brandeis University, The Brigham and Women's Hospital, Inc.
    Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Suresh K. Gorla, Mandapati Kavitha
  • Patent number: 9433610
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: September 6, 2016
    Assignees: Massachusetts Eye & Ear Infirmary, The Brigham and Women's Hospital, Inc.
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • Patent number: 9359363
    Abstract: Herein, methods of modulating inclusion formation and stress granules in cells are described. The methods comprise contacting a cell with an inclusion inhibitor. Methods for screening for modulators of TDP-43 aggregation are also described.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: June 7, 2016
    Assignees: AQUINNAH PHARMACEUTICALS, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Benjamin Wolozin, Marcie Glicksman, Gregory D. Cuny, Justin Boyd
  • Publication number: 20160115167
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: March 4, 2014
    Publication date: April 28, 2016
    Inventors: Paul B. Yu, Gregory D. Cuny, Agustin H. Mohedas, Kenneth D. Bloch, Randall T. Peterson
  • Publication number: 20160102053
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Application
    Filed: July 10, 2015
    Publication date: April 14, 2016
    Inventors: Gregory D. CUNY, Xin TENG, Junying YUAN, Alexei DEGTEREV, John A. PORCO, JR.
  • Publication number: 20160052935
    Abstract: Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.
    Type: Application
    Filed: November 10, 2015
    Publication date: February 25, 2016
    Inventors: Elliot Androphy, Gregory D. Cuny, Jonathan Cherry, Marcie A. Glicksman
  • Publication number: 20160046633
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 18, 2016
    Inventors: Asaf Alimardanov, Gregory D. Cuny, Gurmit Singh Grewal, Arthur Lee, John C. McKew, Agustin H. Mohedas, Min Shen, Xin Xu, Paul B. Yu
  • Publication number: 20160024098
    Abstract: The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Junying YUAN, Alexei DEGTEREV, Gregory D. CUNY
  • Patent number: 9212209
    Abstract: Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: December 15, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Elliot Androphy, Gregory D. Cuny, Jonathan Cherry, Marcie A. Glicksman
  • Publication number: 20150336902
    Abstract: This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such disorders include obesity and disorders associated with obesity.
    Type: Application
    Filed: July 29, 2015
    Publication date: November 26, 2015
    Inventors: David Cohen, Neil Wagle, Gregory D. Cuny, Jun Xian, Marcie Glicksman, Ross L. Stein, Ekaterina Y. Shishova
  • Patent number: 9187421
    Abstract: The invention is directed to compounds according to formula (I): where R1 is L1C(O)OT or L1C(O)OL2C(O)OT; R2 is a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or R1; n is an integer from 0 to 5; each R3 is independently halogen or R2; R4 and R5 are independently H, halogen, CN or CF3; L1 and L2 are each independently a bond, a substituted or unsubstituted C1-C10 alkylene, C2-C10 alkenylene, or C2-C10 alkynylene; and T is H, a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, nitrophenol, or cyclopropyl. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and to methods for providing anesthesia in mammals by administering such a pharmaceutical composition.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: November 17, 2015
    Assignees: THE GENERAL HOSPITAL CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Douglas E. Raines, Joseph F. Cotten, Stuart A. Forman, Keith W. Miller, Syed S. Husain, Gregory D. Cuny
  • Patent number: 9126938
    Abstract: This invention relates to compounds of Formulas I, II, and III, and their use as inhibitors of phosphatidylcholine transfer protein (PC-TP). The invention further relates to pharmaceutical compositions and methods of treatment of disorders related to the inhibition of PC-TP using the compounds of Formulas I, II, and III. Such disorders include obesity and disorders associated with obesity.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: September 8, 2015
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: David Cohen, Neil Wagle, Gregory D. Cuny, Jun Xian, Marcie Glicksman, Ross L. Stein, Ekaterina Y. Shishova
  • Patent number: 9108955
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: August 18, 2015
    Assignees: President and Fellows of Harvard College, Tufts University, The Brigham and Women's Hospital, Inc., Trustees of Boston University
    Inventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterev, John A. Porco, Jr.